Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Metformin for Melasma in Latin American Women
NCT06845540Phase 2
Key facts
- Status
- Recruiting
- Start
- Feb 2025
- Primary completion
- May 2025
- Countries
- 1
- Sponsor
- University of Puerto Rico
- Modality
- Small Molecules
- Conditions
- melasma
01
Overview
Phase 2, open-label, single-arm trial of liquid metformin (Aspargo Labs) in melasma, sponsored by University of Puerto Rico. Primary endpoint: modified Melasma Area and Severity Index at 12 weeks. Started Feb 2025; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Metformin
Oral metformin tablets starting at 500 mg daily, increasing to 500 mg twice daily at week 4.
03
Endpoints
Primary
modified Melasma Area and Severity Index
Beyond the preview
Go deeper on NCT06845540.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06845540.